Mistral (Dienogest, Ethinylestradiol)

Dienogest/Ethinylestradiol, the active ingredient in Mistral, is a combined estrogen‑progestogen oral contraceptive presented as a combined oral tablet for oral use. It is prescribed to prevent pregnancy and to provide hormonal cycle regulation in women of reproductive age.

GNH USA supplies Mistral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mistral, a combined estrogen‑progestogen oral contraceptive, is indicated for hormonal contraception and related menstrual disorders.

- Contraception: provides reliable prevention of pregnancy in women of reproductive age. - Menstrual cycle regulation: helps to achieve more predictable menstrual bleeding patterns. - Acne management: can improve acne associated with androgen excess in women.

Oral administration of Mistral may be associated with a range of adverse reactions, which are generally classified by frequency.

Common Side Effects: - Nausea: mild to moderate stomach upset, often transient. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort of the breasts. - Breakthrough bleeding: spotting between periods. - Weight fluctuation: mild changes in body weight. - Mood changes: irritability or mild mood swings.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism. - Hepatic dysfunction: jaundice or abnormal liver enzymes. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Mistral, clinicians should evaluate individual risk factors and contraindications.

- Contraindications: avoid use in women with a history of thromboembolic disease, estrogen‑dependent tumors, or active liver disease. - Smoking: do not prescribe to women over 35 who smoke, due to increased cardiovascular risk. - Cardiovascular risk: assess hypertension, diabetes, or hyperlipidaemia before initiation. - Pregnancy and lactation: discontinue if pregnancy is confirmed; safety during breastfeeding is not established. - Drug interactions: review concomitant medications that may affect clotting or hormone metabolism. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Mistral can interact with several medicines that alter hormone metabolism or increase clotting risk.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may reduce efficacy of anticoagulation, increasing thrombosis risk. - Hepatic enzyme inducers (e.g., rifampicin, carbamazepine): can markedly lower plasma levels of ethinylestradiol and dienogest, reducing contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase the risk of bleeding when combined with hormonal therapy. - Antifungal agents (e.g., ketoconazole): can raise hormone concentrations, potentially enhancing side‑effects. - Antiretrovirals (e.g., protease inhibitors): may alter hormone metabolism; monitor for reduced contraceptive reliability.